We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Atrial Fibrillation Management in Congestive Heart Failure With Ablation (AMICA)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00652522
First Posted: April 3, 2008
Last Update Posted: August 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
St. Jude Medical
  Purpose
It is the purpose of the study to show the benefit of the endocardial catheter ablation by pulmonary vein isolation in patients with persistent or longstanding persistent atrial fibrillation, low LVEF and requiring ICD or CRT-D therapy compared to the best medical treatment with antiarrhythmic drugs.

Condition Intervention
Persistent Atrial Fibrillation Heart Failure ICD Device: ICD/CRT implant Procedure: AF ablation Other: Best Medical Treatment

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Atrial Fibrillation Management in Congestive Heart Failure With Ablation

Resource links provided by NLM:


Further study details as provided by St. Jude Medical:

Primary Outcome Measures:
  • Left ventricular ejection fraction (LVEF) by transthoracic echocardiography (TTE) [ Time Frame: 12months ]
    evaluated by Core Lab


Secondary Outcome Measures:
  • Recurrence of atrial tachyarrhythmia [ Time Frame: 9 months ]
    diagnosed by daily ECG via ECG-recording card

  • Exercise capacity in 6 min walk test [ Time Frame: 12 months ]
  • Quality of life [ Time Frame: 12 months ]
    assessed by Minnesota Quality of Life Questionnaire

  • AF burden [ Time Frame: 9 months ]
    assessed by ICD/CRT-D device memory in SJM devices

  • Adverse events [ Time Frame: 12 months ]
  • Mortality [ Time Frame: 12 months ]
  • Number of adequate and inadequate ICD interventions [ Time Frame: 12 months ]

Enrollment: 202
Actual Study Start Date: January 2008
Study Completion Date: July 13, 2017
Primary Completion Date: July 13, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A
Best Medical Treatment, ICD/CRT implant
Device: ICD/CRT implant
Implantation of a ICD/ CRT device if not yet implanted
Other Names:
  • ICDs/ CRT-Ds: All St. Jude Medical device
  • RA, RV and LV leads: St. Jude Medical CE-marked leads recommended
Other: Best Medical Treatment
Best medical treatment according to current guidelines for Management of Patients with Atrial Fibrillation and for Management of Chronic Heart Failure.
Other Name: Conventional rate or rhythm control according valid guidelines
Experimental: B
AF Ablation, ICD/CRT implant
Device: ICD/CRT implant
Implantation of a ICD/ CRT device if not yet implanted
Other Names:
  • ICDs/ CRT-Ds: All St. Jude Medical device
  • RA, RV and LV leads: St. Jude Medical CE-marked leads recommended
Procedure: AF ablation
Atrial Fibrillation ablation by pulmonary vein isolation
Other Names:
  • Catheters: St. Jude Medical CE-marked catheters recommended
  • NavX system for 3D mapping

Detailed Description:

Atrial fibrillation is the most common sustained cardiac arrhythmia affecting 5% of people older than 65 years. It is associated with a 5 times increase of the risk of stroke in patients who are not receiving anticoagulant therapy and a doubling of the rate of death in all patients.

Congestive heart failure (CHF) and atrial fibrillation (AF) often co-exist, where one condition is promoting the development of the other and worsens its condition.

It is the purpose of the study to show the benefit of the endocardial catheter ablation by pulmonary vein isolation in patients with persistent (for a minimum of 1 week to a maximum of 1 year duration) or longstanding persistent (for a minimum of 1 year to a maximum of 4 years) atrial fibrillation, low LVEF (<=35%) and requiring ICD or CRT-D therapy compared to the best medical treatment with antiarrhythmic drugs.

Patients meeting the inclusion and exclusion criteria will be randomized in a 1:1 fashion in an unblinded, parallel arm treatment format to either drug therapy (directed at rate or rhythm control) or catheter ablation.

All therapies will be established and optimized in a 3 month treatment initiation phase (Blanking Period) starting with randomization. For all morbidity and mortality end-points, intention-to-treat analysis will begin at randomization. Efficacy with respect to AF treatment will be established for long-term follow up beginning after 3-month initiation phase.

Improvement of LVEF within 12 month is the primary endpoint of this study. The transthoracic echocardiographic (TTE) assessment at enrollment, discharge and 12 months follow-up follows a standardized protocol. The assessments are analyzed, calculated and expressed by an independent Core Lab.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Having signed and dated Patient Informed Consent
  • Having an indication for ICD or CRT-D therapy as indicated by current valid guidelines or having been implanted with an ICD or CRT-D
  • Symptomatic atrial fibrillation (persistent AF (for a minimum of 1 week to a maximum of 1 year) or longstanding persistent AF (for a minimum of 1 year to a maximum of 4 years)) irrespective of the duration of paroxysmal AF
  • Ejection fraction ≤ 35% as assessed by transthoracic echocardiography
  • Left atrial diameter of less than 60 mm in parasternal diameter during transthoracic echocardiographic study
  • ECG documentation of atrial fibrillation (ECG, Holter, event recorders, etc) related to symptomatic episodes
  • Having typical symptoms of heart failure NYHA II - III
  • Patients > 30 days under optimal medical treatment for heart failure and CRT therapy in case of a pre-implanted CRT-D device
  • Age 18 - 75 years
  • Willing to participate in randomized trial
  • Willing and able to participate in 12 months follow-up period

Exclusion Criteria:

  • Longstanding persistent (> 4 years history) or paroxysmal atrial fibrillation
  • Having a previously implanted pacemaker
  • Having underlying valvular heart disease unless the disease has been corrected
  • Patients with acute myocardial infarction
  • Patients who have had previous pulmonary vein isolation procedures
  • Patients with atrial fibrillation secondary to a reversible cause
  • Known presence of intracardiac or other thrombi
  • Pregnant females or those of child bearing potential who have not had a negative pregnancy test within 48 hours before treatment
  • Patients with other medical condition (i.e., cancer, alcoholism, drug abuse) that may cause the patient to be non-compliant with the protocol, confound the data interpretation or is associated with limited life-expectancy (i.e., less than one year)
  • History of bleeding diathesis or suspected pro-coagulant state
  • Contraindication to anticoagulation therapy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00652522


Locations
Germany
Herz- und Gefaesszentrum Bad Bevensen
Bad Bevensen, Germany, 29549
Universitäts-Herzzentrum Freiburg - Bad Krozingen
Bad Krozingen, Germany
Kerckhoff-Klinik gGmbH
Bad Nauheim, Germany
Universitätsmedizin Berlin - Charité Campus Virchow-Klinikum (CVK)
Berlin, Germany
Herzzentrum Dresden
Dresden, Germany, 01307
Asklepios Klinik St. Georg
Hamburg, Germany, 20099
Universitäres Herzzentrum Hamburg GmbH / UKE
Hamburg, Germany
Klinikum der Ruprecht-Karls-Universität Heidelberg
Heidelberg, Germany
Klinikum Ingolstadt GmbH
Ingolstadt, Germany
Herzzentrum Leipzig GmbH
Leipzig, Germany, 04289
Klinikum der Stadt Ludwigshafen am Rhein gGmbH
Ludwigshafen, Germany
Klinikum Großhadern der Ludwig-Maximilians-Universität
München, Germany
Herzzentrum am Universitätsklinikum Münster
Münster, Germany
St. Adolf-Stift Reinbek
Reinbek, Germany
Hungary
Semmelweis University
Budapest, Hungary
Spain
Hospital Universitari Clinic
Barcelona, Spain
Sponsors and Collaborators
St. Jude Medical
Investigators
Principal Investigator: Karl-Heinz Kuck, Prof. Asklepios Klinik St. Georg - Hamburg
  More Information

Responsible Party: St. Jude Medical
ClinicalTrials.gov Identifier: NCT00652522     History of Changes
Other Study ID Numbers: AF06003AF
First Submitted: March 20, 2008
First Posted: April 3, 2008
Last Update Posted: August 11, 2017
Last Verified: August 2017

Keywords provided by St. Jude Medical:
AF ablation
Pulmonary vein isolation(PVI)
reduced LV ejection fraction
symptomatic atrial fibrillation
persistent AF

Additional relevant MeSH terms:
Heart Failure
Atrial Fibrillation
Heart Diseases
Cardiovascular Diseases
Arrhythmias, Cardiac
Pathologic Processes